ALKERMES: Alkermes to Present New Data From Mental Health Portfolio at the American Society of Clinical Psychopharmacology 2019 Annual Meeting


Alkermes issued the following announcement on May 22.

Alkermes plc (Nasdaq: ALKS) today announced plans to present new data from its mental health portfolio at the American Society of Clinical Psychopharmacology (ASCP) 2019 Annual Meeting in Scottsdale, Ariz., May 28-31, including new safety and tolerability data from ALPINE (Aripiprazole Lauroxil and Paliperidone palmitate: INitiation Effectiveness), underscoring the clinical utility of ARISTADA® (aripiprazole lauroxil) and long-acting therapies for schizophrenia. ALPINE was a first-of-its-kind, six-month study evaluating the efficacy, safety and tolerability of ARISTADA and INVEGA SUSTENNA® (paliperidone palmitate) when used to initiate patients experiencing an acute exacerbation of schizophrenia in the hospital and maintain treatment in an outpatient setting.

"Alkermes is one of very few companies focused on advancing science in mental health, and we're committed to developing and delivering medicines that help address the real-world challenges that patients and providers face," said Craig Hopkinson, M.D., Chief Medical Officer and Senior Vice President of Medicines Development and Medical Affairs at Alkermes. "We look forward to sharing this new research with our peers at ASCP and continuing to develop new therapies for patients with serious and complex mental health diseases."

The full list of Alkermes presentations at ASCP includes:

Oral Presentation: "Particle Size Matters: Developing a 1-Day Initiation Regimen for Aripiprazole Lauroxil" will be presented by Peter Weiden, M.D., Alkermes, during the panel "New and Hopefully Improved! Novel Delivery Systems of Antipsychotic Medications for the Treatment of Schizophrenia" on Tuesday, May 28, 2019, 9:00 a.m. MT

Oral Presentation: "A Combination of Olanzapine and Samidorphan for Schizophrenia: Effects on Weight Gain and Metabolic Parameters in the Phase 3 ENLIGHTEN-2 Study and Subsequent Long-Term, Open-Label Safety Study," will be presented by John Newcomer, M.D., South Florida Behavioral Health Network during the Pharmaceutical Pipelines session on Tuesday, May 28, 2019, 1:50 – 4:00 p.m. MT. An accompanying poster (#W12) will be presented on Wednesday, May 29, 2019, 11:15 a.m. – 1:00 p.m. MT

Poster #W4: "The ALPINE Study: A Randomized, Double-Blind, Active-Controlled Study of Starting Aripiprazole Lauroxil with a 1-Day Initiation Regimen in Acutely Ill Patients with Schizophrenia" will be presented by Peter Weiden, M.D., Alkermes, on Wednesday, May 29, 2019, 11:15 a.m. – 1:00 p.m. MT

Poster #W16: "A Phase 3, Multicenter Study to Assess the Long-Term Safety, Tolerability and Efficacy of ALKS 3831 in Subjects With Schizophrenia" will be presented by Sergey Yagoda, M.D., Ph.D., Alkermes, on Wednesday, May 29, 2019, 11:15 a.m. – 1:00 p.m. MT

Poster #T5: "Insulin Sensitivity and Glucose Metabolism of Olanzapine and A Combination of Olanzapine and Samidorphan: Phase 1 Study in Healthy Volunteers" will be presented by William Martin, Ph.D., Alkermes, on Thursday, May 30, 2019, 12:30 – 2:00 p.m. MT

A full list of presentations at the ASCP 2019 Annual Meeting is available at: https://ascpmeeting.org/.

Original source can be found here.

Want to get notified whenever we write about Alkermes ?

Sign-up Next time we write about Alkermes, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.

Organizations in this Story

Alkermes

More News

Metro Business Network